Valuation: Viking Therapeutics, Inc.

Market Cap 2.85B 2.54B 2.35B 2.13B 3.98B 270B 4.05B 28.26B 11.19B 142B 10.68B 10.45B 446B P/E 2026 *
-5.31x
P/E 2027 * -5.72x
Enterprise Value 2.38B 2.13B 1.97B 1.78B 3.33B 226B 3.39B 23.66B 9.37B 119B 8.94B 8.75B 374B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.16%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Viking Therapeutics, Inc.

1 day-5.54%
1 week-3.06%
Current month-25.15%
1 month-41.42%
3 months-31.05%
6 months-25.61%
Current year-30.64%
1 week 24.36
Extreme 24.36
27.29
1 month 24.36
Extreme 24.36
39.05
Current year 24.36
Extreme 24.36
43.1
1 year 24.36
Extreme 24.36
43.15
3 years 8.28
Extreme 8.28
99.41
5 years 2.02
Extreme 2.02
99.41
10 years 0.88
Extreme 0.88
99.41
Manager TitleAgeSince
Chief Executive Officer 60 23/09/2012
Director of Finance/CFO 55 03/01/2021
Chief Tech/Sci/R&D Officer 57 10/06/2026
Director TitleAgeSince
Chairman 68 30/04/2015
Chairman 60 23/09/2012
Director/Board Member 53 30/04/2014
Date Insider Type Main position Quantity % Market Cap. Importance
01/08/26 Free

Director

47,133 0.0404%
29/07/26 Sell

Chief Operating Officer

-18,217 0.0157%
29/07/26 Sell

Founder

-148,517 0.1279%
Change 5-day change 1-year change 3-year change Capi.($)
-5.54%-3.06%-28.07%+135.07% 2.85B
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average -0.31%+1.87%+41.75%+155.30% 38.6B
Weighted average by Cap. +0.35%+2.69%+47.01%+158.40%

Financials

2026 *2027 *
Net sales - -
Net income -542M -484M -447M -405M -757M -51.41B -770M -5.38B -2.13B -26.94B -2.03B -1.99B -84.92B -535M -478M -441M -400M -748M -50.8B -761M -5.31B -2.1B -26.62B -2.01B -1.97B -83.91B
Net Debt -463M -414M -382M -346M -648M -43.99B -659M -4.6B -1.82B -23.05B -1.74B -1.7B -72.66B -511M -456M -421M -382M -714M -48.49B -726M -5.07B -2.01B -25.41B -1.92B -1.88B -80.1B
Projected Income Statement - Annual - Viking Therapeutics, Inc.
Logo Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Employees
65
Date Price Change Volume
23/10/26 US$24.40 -5.54% 4,675,335
22/10/26 US$25.83 -2.08% 3,530,546
21/10/26 US$26.38 -1.24% 3,295,042
20/10/26 US$26.71 +6.63% 4,656,930
19/10/26 US$25.05 -0.48% 3,741,079
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Viking Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
24.40USD
Average target price
95.05USD
Spread / Average Target
+289.56%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Viking Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. VKTX Stock